Prevalence, Incidence, and Factor Concentrate Usage Trends of Hemophiliacs in Taiwan

다국어 초록 (Multilingual Abstract)

Purpose: Hemophilia A and B (HA, HB) are the most common X-linked inherited bleeding disorders. The introduction of factor concentrates has allowed for control of the lifelong chronic disease. However, no studies have been published regarding the epidemiology of hemophilia in Taiwan. Our aim was to determine the prevalence, incidence, and mortality rate, as well as trends in the use of factor concentrates,in individuals with hemophilia in Taiwan. Materials and Methods: A retrospective study was conducted using the National Health Insurance Research Database between 1997 and 2007. Results: We identified 988 males with hemophilia (HA : HB ratio=5.4 : 1). The mean prevalence per 100000 males was 6.7±0.1 for HA and 1.2±0.1 for HB. The estimated mean annual incidence per live male birth was 1 in 10752 for HA and 1 in 47619 for HB. Standardized mortality ratios for males with hemophilia (all severities) or severe hemophilia were 1.3- and 2.1-fold higher than that of the general male population, respectively. Mean factor VIII (FVIII) and factor IX (FIX) usage was 1.5003±0.4029 and 0.3126±0.0904 international units (IUs) per capita, respectively. Mean FVIII and FIX usage per patient with hemophilia (all severities) or severe hemophilia was 44027±11532 and 72341±17298, respectively, and 49407±13015 and 74369±18411 IUs per person with HA or HB, respectively. Conclusion: Our data revealed epidemiologic and factor concentrate usage trends in males with hemophilia in Taiwan, highlighting a need for improvements in the mandatory National Health Insurance registry. A better-designed, patient-centered registry system would enable more detailed patient information collection and analysis, improving subsequent care.

참고문헌 (Reference)

1 Coppola A, "Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies" 16 (16): 13-19, 2010

2 Plug I, "Thirty years of hemophilia treatment in the Netherlands, 1972-2001" 104 : 3494-3500, 2004

3 Franchini M, "The management of hemophilia in elderly patients" 2 : 361-368, 2007

4 Mannucci PM, "The hemophilias--from royal genes to gene therapy" 344 : 1773-1779, 2001

5 Wight J, "The epidemiology of inhibitors in haemophilia A: a systematic review" 9 : 418-435, 2003

6 "Statistics of HIV/AIDS 1984-2007/12/31"

7 "Statistics of HIV/AIDS 1984-2003/1/31"

8 Plug I, "Social participation of patients with hemophilia in the Netherlands" 111 : 1811-1815, 2008

9 Liou WS, "Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan" 17 : 45-54, 2011

10 Carcao MD, "Round Table Group. Prophylaxis in the haemophilia population-optimizing therapy" 13 : 227-232, 2007

11 Chan V, "Restriction fragment length polymorphisms associated with factor VIII: C gene in Chinese" 79 : 128-131, 1988

12 Ettingshausen CE, "Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development" 12 (12): 102-106, 2006

13 Gouw SC, "Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study" 109 : 4693-4697, 2007

14 Coppola A, "Prophylaxis in people with haemophilia" 101 : 674-681, 2009

15 Fischer K, "Prophylaxis for severe haemophilia: clinical and economical issues" 9 : 376-381, 2003

16 Geraghty S, "Practice patterns in haemophilia A therapy -- global progress towards optimal care" 12 : 75-81, 2006

17 "Population by age"

18 Soucie JM, "Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators" 59 : 288-294, 1998

19 "National Health Insurance in Taiwan 2011 Annual Report"

20 Darby SC, "Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV" 110 : 815-825, 2007

21 Plug I, "Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study" 4 : 510-516, 2006

22 Tagliaferri A, "Mortality and causes of death in Italian persons with haemophilia, 1990-2007" 16 : 437-446, 2010

23 Berntorp E, "Modern treatment of haemophilia" 73 : 691-701, 1995

24 Mejia-Carvajal C, "Life expectancy in hemophilia outcome" 4 : 507-509, 2006

25 Goudemand J, "Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A" 107 : 46-51, 2006

26 Street A, "Haemophilia and ageing" 12 (12): 8-12, 2006

27 "Guidelines for the management of hemophilia"

28 Chen YC, "Genetic analysis of haemophilia A in Taiwan" 16 : 538-544, 2010

29 Smith PS, "Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis" 129 : 424-431, 1996

30 Chalmers EA, "Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A" 13 : 149-155, 2007

31 Carlsson KS, "Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden" 10 : 515-526, 2004

32 Heemstra HE, "Cost of severe haemophilia in Toronto" 11 : 254-260, 2005

33 Ling SC, "Children and Adolescents with Haemophilia in Hong Kong: an Epidemiological and Clinical Review" 11 : 13-19, 2006

34 "Cherishing health insurance for a healthy Taiwan 2006"

35 "Causes of death statistics"

36 "Cases of HIV/AIDS by exposure category"

37 Hemophilia A, "Canadian Hemophilia registry-Factor VIII"

38 Hemophilia B, "Canadian Hemophilia registry-Factor IX"

39 Iorio A, "Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis" 14 : 444-453, 2008

40 Ono O, "Assessment of haemophilia treatment practice pattern in Japan" 15 : 1032-1038, 2009

41 "Annual Report 2009. United Kingdom Haemophilia Centre Doctors’ Organisation 2009"

42 Ahmad OB, "Age Standardization of rates: a new WHO standard"

43 Stonebraker JS, "A study of variations in the reported hemophilia B prevalence around the world"

44 Stonebraker JS, "A study of variations in the reported haemophilia A prevalence around the world" 16 : 20-32, 2010

45 Stonebraker JS, "A study of reported factor VIII use around the world" 16 : 33-46, 2010

46 StataCorp LP, "4905 Lakeway Drive College Station"